Official Title
Determination of Efficacy of N-Acetylcysteine in Preventing Those With Mild or Moderate COVID-19 From Progressing to Severe Disease
Brief Summary

The purpose of this study is to assess the efficacy of N-acetylcysteine (NAC) in preventing those with mild or moderate COVID-19 from progressing to severe disease

Detailed Description

After being informed of the study and potential risks and benefits, patients meeting
eligibility requirements will be randomized to receive oral N-acetylcysteine (NAC) as
follows:

Inpatients:

- N-acetylcystine (NAC) 25 mg/kg PO (rounded up to the nearest 600 mg) q4hrs until
discharge

- N-acetylcysteine (NAC) 1200 mg PO BID x 1 week post-discharge

Outpatients:

- N-acetylcysteine (NAC) 2400 mg PO x 1 then 1200 mg PO BID x 2 weeks

Completed
COVID
SARS-COV2
SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere
Oxidative Stress

Drug: N-acetylcysteine

Oral formulation: 600 mg capsules of N-acetylcysteine
Other Name: NAC, acetylcysteine, N-acetyl-L-cysteine, NALC

Eligibility Criteria

Inclusion Criteria:

- known or suspect COVID-19 disease AND one or more of the following influenza-like
symptoms, including: diarrhea vomiting fever (subjective or measured) chills myalgias
fatigue sore throat headache cough nasal/sinus congestion or rhinorrhea shortness of
breath chest pain

Exclusion Criteria:

- Minors, pregnant women and people unable to provide informed consent are excluded from
this study

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
United States
Locations

CHA Cambridge Hospital
Cambridge, Massachusetts, United States

CHA Everett Hospital
Everett, Massachusetts, United States

CHA Respiratory Clinic
Somerville, Massachusetts, United States

CHA Somerville campus
Somerville, Massachusetts, United States

Cambridge Health Alliance
NCT Number
Keywords
Glutathione
Acetylcysteine
Oxidative stress
NAC
Covid
Covid-19
SARS-CoV2
MeSH Terms
COVID-19
Severe Acute Respiratory Syndrome
Acetylcysteine
N-monoacetylcystine